Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YK 012

Next Previous
Drug Profile

YK 012

Alternative Names: YK-012

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Excyte Biopharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase I Membranous glomerulonephritis; Non-Hodgkin's lymphoma

Most Recent Events

  • 12 Jun 2025 Excyte Biopharma plans to initiate a phase Ib/II trial for Systemic lupus erythematosus (Treatment experienced) in China (IV, Infusion), in July 2025 (NCT07010835)
  • 08 Mar 2025 Phase-I clinical trials in Membranous glomerulonephritis in China (IV) (NCT06982729)
  • 28 Aug 2024 Phase-I/II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Monotherapy, Second-line therapy or greater) in China (IV) (NCT06580301)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top